$ENVX

Enovix (NASDAQ:ENVX) Price Target Cut to $5.50 by Analysts at TD Cowen

TD Cowen cut its Enovix (NASDAQ:ENVX) price target to $5.50 from $7.00 and kept a Hold rating, citing a potential upside of 37.67% versus the stock near $4.00. The article also notes other analyst target changes and that ENVX reported Q1 EPS of -$0.14 on revenue of $7.60M.

Original reporting
Published Jul 24, 2026, 5:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 6:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Enovix (NASDAQ:ENVX) Price Target Cut to $5.50 by Analysts at TD Cowen — source image
Decision brief

The 30-second read

$ENVXBearishMed
01

Why it matters

A lower price target with a Hold rating can shift near-term positioning and expectations, especially for a high-beta, loss-making stock where valuation is highly sentiment-driven.

02

Market read

Traders may reassess downside risk and near-term catalysts after a fresh sell-side target reduction, particularly given the stock’s recent weakness.

03

What to watch

The article includes prior guidance and financial ratios but does not connect TD Cowen’s cut to a specific new Enovix operational change, so the market may treat it as sentiment rather than a fundamental reset.

Relevance 7/10Novelty 6/10Timing: after-hours/Friday analyst note, following the stock’s Friday drop to ~$4

Background

The piece summarizes TD Cowen’s latest target change and lists other recent analyst rating/target moves for Enovix.

Company-level read

Ticker impact

$ENVXBearishMedium confidence
Context

TD Cowen cut Enovix’s price target from $7.00 to $5.50 and kept a Hold rating, implying reduced upside versus the prior view.

Expected impact

Short-term downside bias, with potential volatility around the new target and recent ~$4 print.

Evidence & confidence

The article discloses a specific, dated sell-side target reduction (TD Cowen) plus the stock’s recent trading level, but it does not provide new company fundamentals beyond previously reported earnings and guidance.

Market effects

Reinforces cautious sentiment toward early-stage battery technology names, where valuation is sensitive to analyst target revisions.

Limited, as the catalyst is company-specific sell-side research rather than a macro/regional driver.

Low, no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

Despite the TD Cowen cut, other analysts still rate ENVX Buy and the company recently reported revenue growth and beat on EPS versus consensus, which can offset target reductions.

Key entities

  • Enovix

    NASDAQ-listed lithium-ion battery cell developer whose price target was cut by TD Cowen.

  • TD Cowen

    Brokerage that reduced ENVX’s price objective from $7.00 to $5.50 and maintained a Hold rating.

Related articles

$ENVXMed

Enovix, Forte Biosciences rally premarket; PepsiCo slips

U.S. index futures were mixed as investors weighed U.S.-Iran tensions and a rebound in semiconductors. Enovix rose 17% after naming former Apple executive Michael Vyvoda COO. Forte Biosciences gained 12% on positive Phase 1b results for FB102 in vitiligo. Rackspace Technology added 8% on a partnership with Palantir. PepsiCo fell 1.8% after mixed Q2 results.

$ENVXMed

Enovix, Forte Biosciences rally premarket; PepsiCo slips By Investing.com

U.S. index futures were mixed as investors weighed U.S.-Iran tensions and a rebound in semiconductors. In premarket movers, Enovix rose 17% after naming former Apple executive Michael Vyvoda COO to oversee manufacturing ramp in Malaysia and South Korea. Forte Biosciences gained 12% on positive Phase 1b FB102 vitiligo results. Rackspace rose 8% on a Palantir partnership. PepsiCo fell 1.8% after mixed Q2 results.

$ENVXMed

Enovix stock jumps 17% on new COO appointment By Investing.com

Enovix (NASDAQ:ENVX) shares rose about 17% after the company said Michael Vyvoda, formerly an Apple operations leader, will become Chief Operating Officer effective July 29, 2026. He will oversee manufacturing, supply chain and operations engineering as Enovix scales Malaysia and Korea production. Q1 2026 revenue was $7.6M, up 49% YoY, above guidance.

$ENVXMed

Enovix Corporation: Enovix Appoints Former Apple Operations Leader Michael Vyvoda as Chief Operating Officer to Lead Global Manufacturing Ramp

Enovix (Nasdaq: ENVX) appointed Dr. Michael Vyvoda as Chief Operating Officer effective July 29, 2026, to lead global manufacturing, supply chain and operations engineering. The company cited its Q1 2026 results, including 49% YoY revenue growth to $7.6 million and a pipeline for Korea-made products above $130 million, as it ramps production at Malaysia and Korea facilities.